Compare PCTY & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCTY | PCVX |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 7.0B |
| IPO Year | 2014 | 2020 |
| Metric | PCTY | PCVX |
|---|---|---|
| Price | $146.23 | $65.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 11 |
| Target Price | ★ $172.15 | $108.67 |
| AVG Volume (30 Days) | 564.6K | ★ 1.8M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.39 | N/A |
| EPS | ★ 4.92 | N/A |
| Revenue | ★ $1,771,326,000.00 | N/A |
| Revenue This Year | $6.90 | N/A |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | $29.93 | ★ N/A |
| Revenue Growth | ★ 11.04 | N/A |
| 52 Week Low | $92.99 | $39.87 |
| 52 Week High | $161.93 | $90.75 |
| Indicator | PCTY | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 58.82 |
| Support Level | $140.01 | $52.91 |
| Resistance Level | $148.70 | N/A |
| Average True Range (ATR) | 3.82 | 4.04 |
| MACD | 0.04 | 0.98 |
| Stochastic Oscillator | 74.36 | 30.10 |
Paylocity is a cloud-based human capital management provider offering payroll, compliance, and human resources management solutions. With the addition of expense and IT management modules, Paylocity unifies back-office operations spanning HR, finance, and IT on a single platform and bills customers on a subscription basis. The firm's customer base skews toward the midmarket and is primarily based in the US. As of fiscal 2026, Paylocity has nearly 44,400 customers.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.